🟢 Humacyte is trading 6.8% up in pre-market — no clear company-specific catalyst identified

Humacyte is trading 6.8% up at $0.59 before the September 28, 2026 session; no clear company-specific catalyst was identified.

• The latest notable company news was the FDA’s September 9 authorization extending Symvess shelf life from 18 to 36 months.
• A September 10 conference announcement also predates the move. Broader futures are lower, but available evidence does not establish a market-wide explanation for Humacyte’s rise.